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AutophagyBoth BRCA1 and Beclin 1 (BECN1) are tumor suppressor genes, which are in close proximity on the human chromo-
some17q21 breast cancer tumor susceptibility locus and are often concurrently deleted. However, their importance
in sporadic human breast cancer is not known. To interrogate the effects of BECN1 and BRCA1 in breast cancer, we
studied theirmRNAexpression patterns in breast cancer patients from two large datasets: The CancerGenomeAtlas
(TCGA) (n = 1067) and the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) (n =
1992). In both datasets, low expression of BECN1 was more common in HER2-enriched and basal-like (mostly
triple-negative) breast cancers compared to luminal A/B intrinsic tumor subtypes, and was also strongly associated
with TP53mutations and advanced tumor grade. In contrast, there was no signiﬁcant association between low
BRCA1 expression and HER2-enriched or basal-like subtypes, TP53mutations or tumor grade. In addition, low ex-
pression of BECN1 (but not low BRCA1) was associatedwith poor prognosis, and BECN1 (but not BRCA1) expression
was an independent predictor of survival. Theseﬁndings suggest that decreasedmRNA expression of the autophagy
gene BECN1may contribute to the pathogenesis and progression of HER2-enriched, basal-like, and TP53mutant
breast cancers.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Estrogen-receptor (ER) negative breast cancer comprises 25–30% of
all sporadic breast cancer and is characterized by advanced histological
grade, aggressive clinical behavior, a high rate of metastasis to the braine; BRCA1, breast cancer 1, early
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ie),
B.V. This is an open access articleand lung, and resistance to hormone deprivation therapy (Yersal and
Barutca, 2014; Sorlie et al., 2001; Rakha et al., 2008a). Based on molec-
ular proﬁling (Yersal and Barutca, 2014; Sotiriou and Pusztai, 2009),
these cancers generally fall into two subtypes: (1) HER2-enriched tu-
mors (those with overexpression or ampliﬁcation of human epidermal
growth factor receptor 2 [HER2]) and (2) basal-like tumors (which gen-
erally do not express estrogen or progesterone receptors or HER2/neu,
but have high levels of basal markers and/or epidermal growth factor
receptor expression and a high rate of TP53 mutations) (Sorlie et al.,
2001; Perou et al., 2000).
The pathogenesis of the basal-like subtype has not been deﬁned, but
some studies have suggested an association with dysfunction of the
DNA repair BRCA1 pathway (Turner et al., 2004, 2007; Mueller and
Roskelley, 2003;Valentin et al., 2012). Thebasal-like subtype is frequent
in women with BRCA1 germline mutations (Foulkes et al., 2003) who
are at markedly increased risk of breast cancer. Levels of BRCA1 expres-
sion have also been reported to be low in women with sporadic breast
cancers that have basal-like features (Turner et al., 2007; Muellerunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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gosity at the breast cancer tumor susceptibility locus on chromosome
17q21 (Staff et al., 2003) and/or BRCA1 promoter hypermethylation
(Birgisdottir et al., 2006) or increased expression of negative regulatory
factors (Turner et al., 2007; Garcia et al., 2011; Z.Q. Wu et al., 2012).
The essential autophagy gene beclin 1 (BECN1) is a haploinsufﬁcient
tumor suppressor (Liang et al., 1999; Qu et al., 2003; Yue et al., 2003)
that is also located on the breast cancer tumor susceptibility chromo-
somal locus 17q21, ~150 kb centromeric to BRCA1 (Aita et al., 1999).
Monoallelic loss of BECN1 has been observed in about 40% of human
breast cancers (Aita et al., 1999; Li et al., 2010), and enforced expression
of BECN1 in breast cancer cells with allelic loss of 17q21 inhibits prolif-
eration and tumorigenesis (Liang et al., 1999). Heterozygous deletion
of BECN1 in mice leads to an increased incidence of spontaneous carci-
nomas (Qu et al., 2003; Yue et al., 2003), including breast carcinoma
with basal-like features (Cicchini et al., 2014).
Given the likely roles of both BRCA1 and BECN1 in the development
of mammary malignancy and the close proximity of BRCA1 and BECN1
genes on chromosome 17q21, large genomic deletions of the 17q21
locus could increase the risk of sporadic breast cancer through loss of
expression of both genes, or alternatively, through the loss of only one
gene, with loss of the other representing a bystander effect (Laddha
et al., 2014). Therefore, we sought to determine the importance of loss
of BECN1 and of BRCA1 expression inwomenwith ER-negative subtypes
of breast cancer.
2. Methods
2.1. Genetic Proﬁling in Two Breast Cancer Datasets
We interrogated two large independent publicly available breast
cancer datasets: The Cancer Genome Atlas Project (TCGA) in the
United States (Anon., 2012) and Molecular Taxonomy of Breast Cancer
International Consortium (METABRIC) in the United Kingdom and
Canada (Curtis et al., 2012). The patient characteristics in each dataset
are shown in Supplementary Table 1.
TCGA breast cancer mRNA gene expression, copy number alteration,
and clinical data were downloaded from UCSC cancer browser at
https://genome-cancer.ucsc.edu/proj/site/hgHeatmap/ (data processed
in August 2014). TCGA gene expression proﬁle was measured using
the Illumina HiSeq 2000 RNA Sequencing platform. RSEM (RNA-Seq
by Expectation-Maximization) normalized count was used as gene-
level expression estimates in this study. TCGA copy number proﬁle
was measured using genome-wide SNP6 array. Gene-level somatic
copy number alterations were estimated from TCGA FIREHOSE pipeline
(https://conﬂuence.broadinstitute.org/display/GDAC/Home) using the
GISTIC2.0 (Mermel et al., 2011) method. The GISTIC2.0 summarized
the copy number of each gene into−2,−1, 0, 1, 2, representing homo-
zygous deletion, heterozygous deletion, diploid normal copy, low-level
ampliﬁcation, or high-level ampliﬁcation. For analysis, the homozygous
deletion and heterozygous deletion groups were combined. TP53muta-
tion status was also obtained from the TCGA FIREHOSE pipeline using
MutSig method (Lawrence et al., 2013). TCGA tumor grade information
was manually extracted from the pathologic reports provided by the
cBio portal. ER, progesterone receptor (PR), and HER2 status was
deﬁned by protein expression (measured by immunohistochemistry),
as provided in the original TCGA publication; (Anon., 2012) receptor
status was classiﬁed as positive, negative, or equivocal, with less than
10 samples classiﬁed as equivocal.
In theMETABRIC dataset, mRNA expressionwasmeasured using the
Illumina HT-12 platform. Normalized gene-level expression and copy
number segment ﬁles from METABRIC were downloaded from the
European Genome-phenome Archive (EGA) with accession number
EGAS00000000083. The copy number proﬁle of METABRIC data was
measured using the Affymetrix SNP6 array. As for the TCGA, the copy
number data of theMETABRIC cohortwasprocessed using theGISTIC2.0(Mermel et al., 2011) algorithm to identify homozygous deletion, het-
erozygous deletion, diploid normal copy, low-level ampliﬁcation or
high-level ampliﬁcation for each gene for each sample. Clinical variables
were obtained from Supplementary Tables 2 and 3 of the original
METABRIC publication (Curtis et al., 2012). ER, PR and HER2 status
was determined bymRNA expression as positive or negative, as deﬁned
in the original METABRIC publication (Curtis et al., 2012).
Intrinsic subtyping was performed using the research-based 50-
gene prediction analysis of microarray (PAM50) subtype predictor
(Parker et al., 2009), which classiﬁes tumors into the following groups:
Luminal A, Luminal B, HER2-enriched, basal-like and normal-like. Sam-
ples without PAM50 data or those identiﬁed as normal-like (which
often represent inadequate tumor cellularity) were excluded from the
analysis. For the TCGA dataset, we used subtype calls downloaded
from the database that were based on RNA-Seq measurements. For
theMETABRICdataset,we used the PAM50 subtypes provided in the da-
tabase; basal-like cancers were further reﬁned into two sub-categories
(IntClust categories 4 and 10) based on the clustering analysis of expres-
sion proﬁles as provided in the original METABRIC publication (Curtis
et al., 2012).
2.2. Statistical Analyses
Our ﬁnal analysis focused on 1067 and 1992 primary breast cancers
in the TCGA and METABRIC datasets, respectively. Low versus high-
expression patient groups were deﬁned relative to the median ex-
pression level of all patients in each data set. Chi-square and Fisher's
Exact tests were used to investigate the relationship between dichot-
omized BECN1 or BRCA1 expressions and PAM50 intrinsic tumor sub-
types, TP53 mutation status, advanced tumor grade, and the groups
deﬁned by ER, PR, and HER2 status. To reduce potential bias from di-
chotomization, the expression levels of BECN1 and BRCA1 were also
displayed as a continuous variable and were compared across differ-
ent PAM50 subtypes, TP53mutation status and tumor grades using a
t-test. All cut-off values were set before analysis, and all tests were
two-tailed.
Survival analysis was performed only in the METABRIC dataset be-
cause of the long median duration of follow-up (7.3 years in
METABRIC and b2 years in TCGA), using the survival R package. Patients
were grouped based on themRNA expression of BECN1 or BRCA1 genes,
with the upper 25%, 25–75% and lower 25% representing the high, inter-
mediate and low expression groups, respectively. Survival curves of the
three groups were estimated by the Kaplan–Meier method and com-
pared using the Cox regression model assuming an ordered trend for
the three groups as previously described (Cheng et al., 2013; Shedden
et al., 2008) and the log-rank test was used to compare the overall sur-
vival curves among three groups. Only deaths related to breast cancer
(disease-speciﬁc deaths) were considered in the analysis. Multivariate
survival analysis using the Cox regression model was performed to as-
sess the relative contribution of BECN1 or BRCA1 mRNA expression,
after adjusting for age, tumor grade, size, stage, molecular subtype,
TP53mutation and perioperative therapy.
3. Results
3.1. Correlation of BECN1 and BRCA1 Deletions
BECN1 and BRCA1 were each deleted in approximately one-third of
the breast tumors in both the TCGA and METABRIC datasets (BECN1
deletion in 34% in TCGA and 33% in METABRIC; BRCA1 deletion in 35%
in TCGA and 27% in METABRIC) (Supplementary Table 2). The vast ma-
jority of these deletions represented heterozygous loss (350 of 354 for
BECN1 and 353 of 361 for BRCA1 in the TCGA dataset; 493 of 643 for
BECN1 and 501 of 522 for BRCA1 in theMETABRIC dataset). As expected
due to the close proximity of these two genes on chromosome 17q21,
910
11
12
9
10
11
12
4
6
8
10
4
6
8
10
diploid
(n=464)
deletion
(n=361)
B
R
C
A
1
ex
pr
es
si
on
4
6
8
10
P=4.12E−10
diploid
(n=471)
deletion
(n=354)
B
E
C
N
1
ex
pr
es
si
on
9
10
11
12
P=2.77E−88
A B
BECN1
CNV
BRCA1
CNV
C
E
LumA/B
(n=613)
HER2
(n=67)
Basal
(n=141)
B
E
C
N
1 
ex
pr
es
si
on
P=1.25E-60
WT
(n=516)
Mutant
(n=254)
B
E
C
N
1 
ex
pr
es
si
on
G
I
(n=76)
II
(n=320)
III
(n=306)
9
10
11
12
B
E
C
N
1 
ex
pr
es
si
on
 Pam50 Subtypes
TP53 Status
Tumor Grade
P=5.01E−20
I
(n=76)
II
(n=320)
III
(n=306)
4
6
8
10
B
R
C
A
1 e
xp
re
ss
io
n
WT
(n=516)
Mutant
(n=254)
B
R
C
A
1 
ex
pr
es
si
on
TP53 Status
Tumor Grade
F
H
LumA/B
(n=613)
HER2
(n=67)
Basal
(n=141)
B
R
C
A
1 
ex
pr
es
si
on
P=6.27e−05
 Pam50 Subtypes
D
13
12
P=0.0461P=3.46E−35
13
12
1213
P=0.191
P=0.0707
LumA/B
(n=162)
HER2
(n=52)
Basal
(n=78)
9
10
11
12
B
E
C
N
1 
ex
pr
es
si
on
I J
LumA/B
(n=158)
HER2
(n=51)
Basal
(n=77)
4
6
8
10
P=1.85E−17
P=0.00012
P=0.654
P=0.278
Pam50 Subtypes 
(BRCA1 deletion group)
Pam50 Subtypes  
(BECN1 deletion group)
P=0.109
P=6.85E−16
P=5.39E−05
13 12
Fig. 1. Boxplot showing the distribution of BECN1 expression and BRCA1 expression in
TCGA, according to copy number status (panels A and B), PAM50 subtypes (panels C
and D), TP53 mutation status (panels E and F), tumor grade (panels G and H), and
PAM50 subtypes in copy number loss subgroups (panels I and J). The boxes represent
the median (black middle line) and the 25th–75th percentiles (lower and upper box
borders). Units for gene expression represent log2 RSEM counts (see Methods).
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events were highly correlated (Supplementary Table 2).
In contrast to a previous report by Laddha et al. (2014), our analyses
of TCGA (n = 1033 samples) did not reveal a signiﬁcant difference be-
tween the number of BECN1 alone (n=3) versus BRCA1 alone deletions
(n = 10) (P = 0.095). Moreover, in the METABRIC dataset (n = 1929
samples), BECN1 alone deletions (without BRCA1 deletions) (n = 153)
were signiﬁcantly more common than BRCA1 alone deletions (without
BECN1deletions) (n=32) (P=1.5E−19). Therefore,when discordant,
BECN1 deletions were more common than BRCA1 deletions.
Nonetheless, since themajority of breast cancer cases with BRCA1 or
BECN1 copy number alteration contain concurrent deletions of both
BRCA1 and BECN1, it is difﬁcult to use copy number alterations as a
parameter for distinguishing the effects of these two genes in breast
cancer. Genes with a high correlation between their copy number and
mRNA expression are more likely to be driver genes and regulate tu-
morigenesis, since gene expression rather than copy number better
deﬁnes phenotype (Akavia et al., 2010). Notably, the relationship be-
tween copy number loss and mRNA expression was more signiﬁcant
for BECN1 than for BRCA1 in both the TCGA dataset (P= 2.77E−88 and
P = 4.12E−10, respectively) (Fig. 1A–B) and the METABRIC dataset
(P = 6.87E−31 and P = 5.02E−8, respectively) (Fig. 2A–B).
3.2. Association of low BECN1 mRNA Expression with HER2-Enriched and
Basal-Like Tumor Subtypes, TP53 Mutations, and Advanced Tumor Grade
In TCGA dataset, themRNA expression of BECN1, but not BRCA1, was
associated with ER-negative intrinsic subtypes and aggressive features
(Table 1). As compared with a high level of BECN1mRNA expression,
a low level of BECN1 mRNA expression was strongly associated
with HER2-enriched breast tumors (odds ratio 8.5 [95% CI 4.4 to 17.9],
P = 8.5E−14); with basal-like breast tumors (odds ratio 35.5
[95% CI 16.4 to 91.8], P = 3.8E−43); with the presence of TP53
mutations (odds ratio 7.1 [95% CI 5.0 to 10.4], P = 2.6E−32), and
with tumor grade III (odds ratio 10.3 [95% CI 5.6 to 19.2], P = 2.4E
−17). In contrast, low levels of BRCA1mRNA expression were not sig-
niﬁcantly associated with any of these features. Low BECN1 (but
not BRCA1) expression was also associated with HER2-positive and
triple-negative tumors identiﬁed by immunohistochemical staining
(Supplementary Table 3).
In TCGA dataset, among four distinct groups with low BECN1/low
BRCA1, low BECN1/high BRCA1, high BECN1/low BRCA1, and high
BECN1/low BRCA1 expression, only low BECN1 expression (regardless
of BRCA1 expression) was related to the frequency of HER2 and basal-
like subtypes, TP53 mutations, and grade III tumors (Supplementary
Fig. 1). Basal-like breast tumors were seen in 42.0% of patients who
had low BECN1 but high BRCA1 expression but in only 0.7% of patients
who had high BECN1 but low BRCA1 expression (P = 9.05E−17 for
the difference between groups) (Supplementary Fig. 1A). Similarly, as
compared with the high BECN1/low BRCA1 expression group, tumors
with low BECN1/high BRCA1 expression were more likely to be HER2-
enriched (14.3% versus 0.7%, P = 4.46E−05); have TP53 mutations
(57.5% versus 9.2%, P= 2.69E−16); and exhibit grade III characteristics
(68.5% versus 20.0%, P = 1.61E−17) (Supplementary Fig. 1B–D).
The association between mRNA expression of BECN1 (but not
BRCA1) and ER-negative tumors was conﬁrmed in the METABRIC
dataset (Table 2). As compared with a high level of BECN1 mRNA ex-
pression, a low level of BECN1mRNAexpressionwas strongly associated
with HER2-enriched breast tumors (odds ratio 5.5 [95% CI 4.0 to 7.7],
P = 1.4E−30); with basal-like breast tumors (odds ratio 10.0 [95% CI
7.3 to 14.1], P = 1.4E−61); with TP53 mutations (odds ratio 3.0 [95%
CI 1.9 to 4.8], P = 8.9E−07); and with tumor grade III (odds ratio 2.9
[95%CI 2.0 to 4.1], P=5.8E−10). Low levels of BRCA1mRNAexpression
were not signiﬁcantly associated with any of these features, and low
BRCA1 levels were actually inversely associated with tumor grade III
(odds ratio 0.4 [95% CI 0.3–0.5], P = 1.1E−08). Low BECN1 (but
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Fig. 2. Boxplot showing the distribution of BECN1 expression and BRCA1 expression in
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triple-negative tumors identiﬁed by mRNA expression analysis
(Supplementary Table 3).
Analysis of the METABRIC dataset also conﬁrmed that low BECN1
expression, independently of BRCA1 expression, was associated with an
increased frequency of basal-like and HER2-enriched tumors, TP53muta-
tions, and tumor grade III. Basal-like breast tumors were seen in 31.0% of
patients who had low BECN1 but high BRCA1 expression but in only 4.3%
of patients who had high BECN1 but low BRCA1 expression (P =
3.39E−24 for the difference between groups) (Supplementary Fig. 1E).
Similarly, as compared with the high BECN1/low BRCA1 expression
group, tumors with low BECN1/high BRCA1 expression were more likely
to be HER2-enriched (21.7% versus 4.6%, P= 2.74E−13); have TP53mu-
tations (22.1% versus 6.7%, P = 4.32E−05); and exhibit grade III charac-
teristics (65.7% versus 29.8%, P=1.19E−24) (Supplementary Fig. 1F–H).
These ﬁndings were conﬁrmedwhen gene expressionwas compared
across different tumor subtypes without dichotomization. In TCGA,
BECN1 (but not BRCA1) expression was signiﬁcantly lower in basal-like
(P = 1.25E−60) and HER2-enriched tumors (P = 6.85E−16), tumors
with TP53mutations (P=3.46E−35), and tumorswith an advanced his-
tological grade (P = 5.39E−05 for grade II, P = 5.01E−20 for grade III)
(Fig. 1C–H). Similarly, in the METABRIC cohort, BECN1 (but not BRCA1)
expression was also signiﬁcantly lower in basal-like (P = 3.52E−79)
and HER2-enriched tumors (P = 3.51E−40), tumors with TP53muta-
tions (P = 1.91E−09), and tumors with an advanced histological
grade (P = 2.79E−07 for grade III) (Fig. 2C–H). In the TCGA (but not
in METABRIC) dataset, despite higher median values for BRCA1 expres-
sion in basal-like tumors, a small proportion had very low levels of
BRCA1 expression (Fig. 1D).
Similar results conﬁrmed the association of low BECN1 expression
with ER-negative tumor subtypes when the analyses were conﬁned to
tumors with BRCA1 deletions. In TCGA dataset (Supplementary
Table 4), low BECN1 expressionwas associatedwith basal-like breast tu-
mors (odds ratio 8.3 [95% CI 4.2 to 17.3], P= 3.8E−12), HER2-enriched
breast tumors (odds ratio 3.5 [95% CI 1.7 to 7.1], P = 1.7E−04), and
tumors with TP53 mutation (odds ratio 3 · 1 [95% CI 1.8 to 5.3], P =
1.0E−05). In the METABRIC dataset (Supplementary Table 4), low
BECN1 expression was associated with basal-like breast tumors (odds
ratio 5.6 [95% CI 3.4 to 9.6], P = 5.5E−13), HER2-enriched breast tu-
mors (odds ratio 4.1 [95% CI 2.5 to 6.7], P = 8.8E−10), tumors with
TP53 mutation (odds ratio 2.3 [95% CI 1.1 to 4.9], P = 0.017), and
grade III tumors (odds ratio 3.4 [95% CI 1.5–8.5], P = 0.002). In both
the TCGA and METABRIC datasets, in the BECN1 deletion subgroup,
low BRCA1 expression was not associated with ER-negative tumor sub-
types, TP53mutations or advanced tumor grade; in fact, in METABRIC,
low BRCA1 expression was inversely associated with HER2-
enriched (odds ratio 0.5 [95% CI 0.3–0.8], P = 0.0018) and grade III
tumors (odds ratio 0.3 [95% CI 0.2–0.6], P5.5E−04) (Supplementary
Table 4). In both TCGA and METABRIC, when gene expression was
compared across different tumor types without dichotomization,
BECN1 expression in the BRCA1 deletion group was signiﬁcantly
lower in HER2-enriched tumors (P = 0.00012 and P= 2.21E–09, re-
spectively) and basal-like tumors (P = 1.85E–17 and P = 1.85E–15,
respectively) (Fig. 1I, Fig. 2I). In contrast, there was no association
between low BRCA1 expression and these ER-negative PAM50 sub-
types in the BECN1 deletion group (Fig. 1J, Fig. 2J).
In a subgroup analysis of patients who were diploid for BECN1 and
BRCA1, in both the TCGA and METABRIC datasets, we also found that
low BECN1 mRNA expression but not low BRCA1 mRNA expression
was associated with HER2-enriched and basal-like tumor subtypes,
TP53 mutations, and grade III tumors (Supplementary Table 5).
Moreover, for both TCGA andMETABRIC datasets, low BECN1 expres-
sion was associated with these same features in patients with high
BRCA1 expression (Supplementary Table 6) or low BRCA1 expression
(Supplementary Table 7). In contrast, low BRCA1 expression was not
positively associated with any of these features in high BECN1 or low
259H. Tang et al. / EBioMedicine 2 (2015) 255–263BECN1 expression subgroups (Supplementary Tables 6 and 7). Low
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Table 1
BECN1 and BRCA1 expression association with clinical features (TCGA cohort).
BECN1 expression BRCA1 expression
mRNA expression Odds ratio
(95% conﬁdence interval)
P value mRNA expression Odds ratio
(95% conﬁdence interval)
P value
High Low High Low
PAM50 subtypes
Luminal A/B 399 214 Reference 348 265 Reference
HER2-enriched 12 55 8.5 [4.4, 17.9] 8.5E−14 37 30 1.1 [0.6, 1.8] 0.90
Basal-like 7 134 35.5 [16.4, 91.8] 3.8E−43 82 59 0.9 [0.6, 1.4] 0.78
TP53 mutation
Wild type 337 179 Reference 2.6E−32 300 216 Reference
Mutant 53 201 7.1 [5.0, 10.4] 138 116 1.1 [0.8, 1.5] 0.49
Tumor grade
I 55 21 Reference 0.003 25 51 Reference
II 171 149 2.3 [1.3, 4.2] 2.4E−17 133 187 0.7 [0.4, 1.2] 0.19
III 62 244 10.3 [5.6, 19.2] 145 161 0.5 [0.3, 0.9] 0.03
260 H. Tang et al. / EBioMedicine 2 (2015) 255–263expression and a reduced odds of grade III tumors. This was observed in
both patients with high BECN1 expression (Supplementary Table 6) or
low BECN1 expression (Supplementary Table 7).
3.3. Association Between Low BECN1 mRNA Expression and Worse Patient
Survival
Patients whose tumors had the lowest levels of BECN1 expression
had the worst prognosis (P = 2.15E−11) (Fig. 3A). In contrast, the
level of BRCA1 expression was not associated with survival (P =
0.164). Similar results were observed when the analyses were
restricted to ER-negative intrinsic subtypes. Overall, the level of BECN1
expression was directly associated with length of survival in patients
with HER2-enriched tumors (P = 3.79E−04) (Fig. 3C), basal-like with
IntClust 4 (P = 5.29E−04) (Fig. 3E) and basal-like with IntClust 10
(P= 0.036) (Fig. 3G). In contrast, BRCA1 expression was not associated
with survival in HER2-enriched tumors or in the two basal-like sub-
groups (Fig. 3D, F, and H).
By multivariate analysis, low BECN1 expression was signiﬁcantly
associatedwith shortened survival, even after adjustment for BRCA1 ex-
pression, age, tumor grade, tumor size, stage, intrinsic subtypes, TP53
mutation and treatment (hazard ratio 0.6 [0.4–0.9], P = 0.02)
(Table 3). Furthermore, in the BRCA1 deletion subgroup, patients with
low BECN1 expression had a signiﬁcantly worse survival than those
with high BECN1 expression (P = 0.00589) (Fig. 3I), whereas in the
BECN1 deletion subgroup, therewas no signiﬁcant relationship between
high and low levels of BRCA1 expression and survival (Fig. 3J).
4. Discussion
As expected due to their close proximity on chromosome 17q21,
BECN1 and BRCA1 are often concordantly deleted or ampliﬁed in breast
cancers. However, our ﬁndings indicate that decreased BECN1 (but not
decreased BRCA1) expression characterizes breast cancers that have
aggressive molecular and clinical characteristics. When compared
with tumors with high levels of expression, tumors with low BECN1
expression were more likely to have a higher histological grade, TP53
mutations, HER2-enriched or basal-like intrinsic subtypes, triple-
negative status, and worse survival. In contrast, the levels of BRCA1
expression did not distinguish tumors with these aggressive character-
istics or unfavorable prognosis. Furthermore, in tumors with deletion of
BRCA1, levels of BECN1 expression provided important additional dis-
criminatory information; however, in tumors with deletion of BECN1,
levels of BRCA1 expression did not distinguish themolecular and clinicalFig. 3.BECN1 expression but not BRCA1 expression is associatedwith disease-speciﬁc survival. Pa
(panel B) expression. Panels C through J: Kaplan–Meier curves within HER2-enriched group (p
andH), and in copy number loss subgroups (panels I and J). Green, red and black lines indicate h
groups, respectively. + denotes censored observations. P values were obtained by the Cox regfeatures of tumors. Importantly, these relationships were observed
across two independent regional databases with different expression
analysis platforms (RNA-seq and microarray), suggesting that our re-
sults cannot be explained by population differences or idiosyncrasies
in the characterization of tumors.
Our ﬁndings are consistent with earlier studies of BECN1 in small
cohorts of patients with breast cancer. Levels of BECN1mRNA expres-
sion have been reported to be reduced in breast cancer (Li et al., 2010;
T. Wu et al., 2012) and have been associated with poor differentiation,
and increased tumor size, proliferation and risk of metastasis (T. Wu
et al., 2012; Yao et al., 2011). In small datasets, low BECN1 mRNA ex-
pression was associated with triple-negative breast cancer (Cicchini
et al., 2014) and with worse prognosis regardless of ER status (Perou
et al., 2000; Dong et al., 2013). In addition, BECN1 DNA copy number
loss has been reported to be associated with HER2 ampliﬁcation and
TP53mutations (Negri et al., 2010).
One previous analysis of TCGA dataset by Laddha et al. (2014) re-
ported deletions of BRCA1 alone but not BECN1 alone in human breast
cancer. That study, however, used an ad hoc heuristic approach for
identifying deletions; our analyses of copy number variations based
on the more rigorous GISTIC method could not conﬁrm this earlier re-
port. In fact, in METABRIC, BECN1 alone deletions were more common
than BRCA1 deletions, indicating a further lack of conﬁrmation of the
ﬁndings of Laddha et al. In addition, Laddha et al. reported that there
were no changes in themean level of BECN1mRNA expression in breast
tumor samples versus normal tissue. However, the validity of this com-
parison is difﬁcult to assess, since epithelial cells (which have very high
levels of BECN1 expression) comprise the majority of cells in tumor
samples but only a small proportion of cells in normal breast tissue.
Most importantly, Laddha et al. considered human breast cancer to
be a homogenous disease and did not analyze the relationship be-
tween BECN1mRNA expression and speciﬁc clinical and pathological
features of breast cancer. Our analyses of two large datasets, TCGA
and METABRIC, revealed a marked association between low BECN1
expression and ER-negative breast cancers subtypes with aggressive
clinical features.
Our ﬁnding that low BRCA1 expression was not associated with
basal-like subtype or worse survival is consistent with the lack of evi-
dence that somatic loss of BRCA1 contributes meaningfully to sporadic
breast cancer. Only homozygous, not heterozygous, Brca1 knockout
mice develop breast cancers (Evers and Jonkers, 2006), whereas breast
(and other) cancers develop in Becn1 heterozygous knockout mice (Qu
et al., 2003; Yue et al., 2003; Cicchini et al., 2014). Moreover, loss of
BRCA1 heterozygosity in humans with germline BRCA1 mutations isnelsA and B:Kaplan–Meier curves for all patients forBECN1 expression (panelA) orBRCA1
anels C and D), Basal/IntClust Memb4 (panels E and F), Basal/IntClust Memb10 (panels G
igh (1st quartile), medium(2nd and 3rd quartiles), and low (4th quartile) expression level
ression model assuming an ordered trend for the three expression groups.
Table 2
BECN1 and BRCA1 expression association with clinical features (METABRIC cohort).
BECN1 expression BRCA1 expression
mRNA expression Odds ratio
(95% conﬁdence interval)
P value mRNA expression Odds ratio
(95% conﬁdence interval)
P value
High Low High Low
PAM50 subtypes
Luminal A/B 804 409 Reference 656 557 Reference
HER2-enriched 63 177 5.5 [4.0, 7.7] 1.4E−30 136 104 0.9 [0.7, 1.2] 0.48
Basal-like 54 277 10.0 [7.3, 14.1] 1.4E−61 168 163 1.1 [0.9, 1.5] 0.29
TP53 mutation
Wild type 423 298 Reference 345 376 Reference 0.52
Mutant 32 67 3.0 [1.9, 4.8] 8.9E−07 51 48 0.9 [0.6, 1.3]
Tumor grade
I 111 59 Reference 53 117 Reference
II 462 313 1.3 [0.9, 1.8] 0.194 371 404 0.5 [0.3, 0.7] 8.3E−05
III 379 578 2.9 [2.0, 4.1] 5.8E−10 526 431 0.4 [0.3, 0.5] 1.1E−08
261H. Tang et al. / EBioMedicine 2 (2015) 255–263necessary for the development of BRCA1mutant-associated breast can-
cers (Futreal et al., 1994). This is likely because haploinsufﬁcient BRCA1
expression is sufﬁcient for full DNA repair (Latimer et al., 2005). Thus,
given the rare frequency of somatic BRCA1 mutations (despite the
high prevalence of BRCA1 heterozygous loss) (Futreal et al., 1994), a
role for BRCA1 deﬁciency in sporadic breast cancer is not established.
Nonetheless, previous studies have shown similarities between the
clinical and molecular features of sporadic basal-like tumors and famil-
ialBRCA1-mutated tumors, resulting in themodel that basal-like tumorsTable 3
Multivariate survival analysis.⁎
Hazards ratio
(95% conﬁdence
interval)
P value
BRCA1 expression 1.0 (0.4, 2.2) 0.95
BECN1 expression 0.6 (0.4, 0.9) 0.02
Age at diagnosis 1.02 (1.00, 1.03) 0.03
Tumor grade
I Reference
II 1.0 (0.5, 2.2) 0.94
III 1.4 (0.7, 3.1) 0.37
Tumor size
b= 20 (T1) Reference
20–50 (T2) 1.6 (1.1, 2.2) 0.01
N50 (T3) 1.5 (0.7, 3.3) 0.27
Tumor stage
Stage 0 Reference
Stage 1 0.8 (0.5, 1.2) 0.31
Stage 2 0.5 (0.3, 0.8) 2.8E−03
Stage 3 1.8 (1.0, 3.2) 0.06
Stage 4 1.7 (0.4, 7.4) 0.46
PAM50 subtype
Luminal A/B Reference
HER2-enriched 0.9 (0.5, 1.6) 0.68
Basal-like 0.6 (0.3, 1.1) 0.07
TP53 mutation status
Wild type Reference
Mutant 2.1 (1.5, 3.0) 7.4E−05
Treatment
Radiation therapy Reference
Hormonal therapy 1.0 (0.5, 2.0) 0.94
Hormonal/radiation therapy 1.5 (0.8, 2.9) 0.20
Chemotherapy 1.5 (0.8, 2.8) 0.17
Chemotherapy/radiation therapy 6.8 (2.6, 17.8) 8.1E−05
Chemotherapy/hormonal therapy 5.4 (2.3, 12.6) 8.7E−05
Chemotherapy/hormonal/radiation therapy 2.2 (0.5, 10.4) 0.32
Radiation therapy 2.3 (1.1, 4.9) 0.04
⁎ Multivariate Cox regression model was performed to assess the relative contribution
of BECN1 or BRCA1mRNAexpression in predicting prognosis, after adjusting for other clin-
ical factors listed in the table. To reduce potential bias from dichotomization, continuous
gene expression values were used.may be associated with BRCA1 dysfunction (Turner et al., 2004, 2007;
Valentin et al., 2012; Turner and Reis-Filho, 2006). Low BRCA1 expres-
sion and/or BRCA1 promoter methylation has been associated with
basal-like sporadic breast cancers in some reports (Turner et al., 2007;
Joosse et al., 2011; Lee et al., 2010; Rakha et al., 2008b), but not others
(Matros et al., 2005; Richardson et al., 2006). Regardless of their
ﬁndings, these studies generally analyzed small numbers of patients;
did not identify tumor subtypes by molecular proﬁling; and identiﬁed
low BRCA1 samples using immunohistochemical staining for protein
expression or quantitative PCR for mRNA expression, which are both
subject to difﬁculties in standardization and reproducibility. Our study
is the ﬁrst to apply current state-of-the-art methods for BRCA1mRNA
quantiﬁcation to a large number of samples characterized by intrinsic
molecular subtypes. Our inability to ﬁnd a relation between BRCA1 ex-
pression and basal-like breast cancers supports the concept that the phe-
notypic similarities of sporadic basal-like breast tumors and hereditary
BRCA1mutated tumors may be explained by factors other than BRCA1
dysfunction (Matros et al., 2005). Alternatively, our data (Fig. 1D) sug-
gests that low BRCA1 expressionmay characterize only a small subgroup
of basal-like tumors,whose speciﬁc features are yet to be deﬁned. Anoth-
er possible explanation is that other factors, besides somatic mutations
or decreased mRNA expression (either as a result of copy number varia-
tion or epigenetic regulation), act to impair BRCA1 function in sporadic
breast cancer. Thus, although our results consistently show a lack of
relationship between decreased BRCA1 expression and basal-like breast
cancer, they cannot deﬁnitively exclude a role for BRCA1 dysfunction in
sporadic basal-like breast cancer.
We propose that the decreased expression of BECN1 (another tumor
suppressor gene located near BRCA1) in sporadic basal-like breast
tumors may partly explain the phenotypic overlap of this disease with
hereditary BRCA1 breast cancer. Patients with germline mutations in
BRCA1 usually have somatic deletion of wild-type chromosome 17q21
in their breast tumors; (Turner et al., 2004; Palacios et al., 2008) thus,
the co-deletion of BECN1 in such cases may contribute to the develop-
ment of basal-like features. Independently of whether the co-deletion
of BECN1 plays a role in hereditary BRCA1 breast cancer, decreased
BECN1 expression — which results in reduced levels of autophagy (Qu
et al., 2003) — may exert effects on the DNA damage repair pathway
in sporadic breast cancer similar to those produced by a BRCA1mutation
and loss of heterozygosity in hereditary breast cancer. In support of this
theory, knockdown of another essential autophagy gene, ATG5, sup-
presses the expression of RAD51, a key protein that functions in homol-
ogous recombination and repair of DNA double-stranded breaks (Mo
et al., 2014).
Taken together, our ﬁndings suggest that decreased BECN1 expres-
sion may contribute to the pathogenesis and/or progression of certain
breast cancers, especially the ER-negative subtypes. A deﬁciency of
BECN1 leads to defects in autophagy (Qu et al., 2003), a lysosomal
262 H. Tang et al. / EBioMedicine 2 (2015) 255–263degradation “housekeeping” pathway that prevents chromosomal in-
stability and DNA damage and inhibits cellular proliferation; (Levine
and Kroemer, 2008) alternatively, loss of other functions of BECN1
(e.g., receptor endocytosis) (Funderburk et al., 2010) may play a role
in carcinogenesis. Future clinical trials should evaluate whether the
level of BECN1 expression predicts the response to speciﬁc chemother-
apeutic regimens or whether strategies that increase BECN1 function
might be therapeutic in patients with low BECN1 expression. Of note,
the autophagy activity of Beclin 1 is inhibited by interaction with BCL-
2 family members (Pattingre et al., 2005; Maiuri et al., 2007), by onco-
genic kinase AKT and EGFR-mediated Beclin 1 post-translational modi-
ﬁcations (Wang et al., 2012; Wei et al., 2013), and by interactions with
HER2 (Han et al., 2013). Thus, currently available Beclin 1/BCL-2 binding
inhibitors, AKT inhibitors, EGFR inhibitors and HER2 inhibitors may act
to increase Beclin 1 function in tumors with low BECN1 expression,
and thereby, improve clinical outcomes.
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